List of Excipients in Branded Drug IOSAT

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Anbex Inc	IOSAT	potassium iodide	51803-001	CELLULOSE, MICROCRYSTALLINE
Anbex Inc	IOSAT	potassium iodide	51803-001	MAGNESIUM STEARATE
Anbex Inc	IOSAT	potassium iodide	51803-001	SILICON DIOXIDE
Anbex Inc	IOSAT	potassium iodide	51803-001	SODIUM THIOSULFATE ANHYDROUS
Anbex Inc	IOSAT	potassium iodide	51803-002	CELLULOSE, MICROCRYSTALLINE
Anbex Inc	IOSAT	potassium iodide	51803-002	MAGNESIUM STEARATE

Excipient Strategy and Commercial Opportunities for IOSAT

Last updated: February 26, 2026

What is IOSAT?

IOSAT, with the active ingredient potassium iodide, is used primarily as a radioactive iodine blocker in nuclear emergencies. It is a licensed drug by the FDA, mainly for thyroid protection in radiation exposure. Marketed by Chinook Therapeutics, the drug is often supplied in tablet form for rapid administration.

Key Excipient Components in IOSAT

Active Ingredient and Formulation

• Potassium iodide (KI) in 130 mg or 65 mg tablets.

• Tablet excipients include:

  • Dextrose or other diluents for tablet formulation.
  • Binding agents such as povidone.
  • Disintegrants like croscarmellose sodium.
  • Lubricants such as magnesium stearate.
  • Coloring agents, if applicable.

Coating and Packaging

• Film coatings to enhance stability and ease of swallowing.
• Blister packs or bottles with desiccants for shelf-life preservation.

Excipient Strategy Overview

Material Selection

• Prioritize excipients with proven stability under high humidity and temperature conditions to meet stockpile demands.
• Use inert excipients that do not interact with potassium iodide, avoiding degradation or loss of potency.

Formulation Optimization

• Aim for excipients that improve disintegration time, bioavailability, and shelf stability.
• Minimize excipient weight to optimize dose portability and compliance.

Regulatory Compliance

• Select excipients with a history of safe use (GRAS status) and regulatory approval.
• Ensure consistency with FDA, EMA, and other international guidelines.

Commercial Opportunities Linked to Excipient Strategy

Supply Chain Enhancements

• Developing relationships with excipient manufacturers that can meet surge demands during emergencies.
• Ensuring multiple sourcing options to avoid supply chain disruptions.

Formulation Improvements

• Innovate low-allergen, non-irritant excipient profiles to expand patient accessibility.
• Explore sustained-release or chewable formulations to enhance ease-of-use in emergency settings.

Shelf Life and Stability Extension

• Use advanced excipients to improve stability, allowing longer storage and reducing waste.
• Enable stockpiling strategies aligned with emergency preparedness timelines.

Customization for Market Expansion

• Develop pediatric or specialized formulations using excipients suitable for sensitive populations.
• Tailor excipient profiles to meet regulatory requirements across different jurisdictions.

Regulatory Pathways and Approvals

• Use excipients with established safety data to accelerate approval processes.
• Streamline registration by aligning formulations with existing regulatory frameworks for radiological countermeasures.

Competitive Landscape

• Limited competition in potassium iodide formulations.
• Major players include BRACCO, Radiogardase, and generic manufacturers.
• Opportunities exist for novel excipient-laden platforms that enhance stability and usability.

Key Considerations

• Stability in extreme environments remains paramount.
• Supply chain resilience influences market viability.
• Formulation innovation focuses on user convenience and safety.

Key Takeaways

• Excipient selection in IOSAT involves inert, stable, and regulatory-approved materials supporting shelf life and usability.
• Material sourcing and formulation enhancements can open avenues for stockpile expansion, especially amid increasing nuclear preparedness.
• Innovations in excipient composition could lead to improved stability, shorter disintegration times, and specialized dosing forms.
• Regulatory alignment and supply chain robustness are critical for commercial success.
• The market remains relatively consolidated; product differentiation via excipient strategies offers competitive advantage.

FAQs

1. What are the main excipients used in IOSAT?
   Povidone, croscarmellose sodium, magnesium stearate, and inert fillers like dextrose.

2. How can excipient choice impact IOSAT’s shelf life?
   Proper excipients enhance stability under storage conditions, extending shelf life and reducing waste.

3. Are there opportunities to develop pediatric formulations of IOSAT?
   Yes, using excipients suitable for children can expand market scope, requiring approval for specific excipients.

4. What regulatory considerations affect excipient strategy in IOSAT?
   Use of excipients with established safety profiles and compliance with international standards expedites approval.

5. How does excipient selection influence supply chain resilience?
   Sourcing stable, widely available excipients mitigates shortages, especially during emergency stockpile buildup.

References

1. FDA. (2021). Guidance for Industry: Excipients in Drug Products.
2. EMA. (2020). Guidelines on excipients in the label and package leaflet.
3. U.S. Pharmacopoeia. (2022). General Chapters: Excipients.
4. Chinook Therapeutics. (2023). Product information for IOSAT.
5. MarketWatch. (2022). Global potassium iodide market analysis.